Global Coronary Artery Disease Therapeutics Market Growth, Share, Size, Trends and Forecast (2025 - 2031)

By Drug Class;

Statins - Beta-Blockers, Calcium Channel Blockers, ACE Inhibitors, Antiplatelet Drugs, and Others.

By Distribution Channel ;

Hospitals ,Online Pharmacies, and Retail Pharmacies.

By Geography;

North America, Europe, Asia Pacific, Middle East & Africa and Latin America - Report Timeline (2021 - 2031).
Report ID: Rn130437995 Published Date: January, 2025 Updated Date: February, 2025

Introduction

Global Coronary Artery Disease Therapeutics Market (USD Million), 2021 - 2031

In the year 2024, the Global Coronary Artery Disease Therapeutics Market was valued at USD 15994.93 million. The size of this market is expected to increase to USD 24050.47 million by the year 2031, while growing at a Compounded Annual Growth Rate (CAGR) of 6.0%.

The COVID-19 pandemic profoundly impacted healthcare systems globally, disrupting usual care in many healthcare facilities and exposing patients with cardiovascular diseases to significant risks. Consequently, the demand for coronary artery disease (CAD) drugs experienced a notable downturn during the pandemic due to the heightened COVID-19 infection risk among cardiovascular patients. A study published in Frontiers in Medicine in December 2021 revealed that 9.1% of patients with CAD symptoms avoided seeking medical attention due to fears of contracting COVID-19. This led to an initial decline in market growth as CAD diagnoses decreased and therapeutic adoption faced obstacles due to stringent lockdowns, supply chain disruptions, and production halts.

In the later stages of the pandemic, market growth saw an upward trajectory, attributed to the increased adoption of CAD therapeutics among COVID-19 patients. For instance, research presented at the American Society of Anesthesiologists annual meeting in October 2022 indicated that 30% of COVID-19 hospitalized patients received statins for high cholesterol, resulting in a 37% lower COVID-19 mortality rate among statin users. This positive impact on market growth stems from the rising utilization of statins in managing COVID-19 complications.

The market's primary drivers include the escalating prevalence of coronary artery disease globally, augmented investments in CAD therapeutics research and development, and the growing prevalence of comorbidities like atherosclerosis and hypertension. The geriatric population, particularly those aged 65 and above, is poised to significantly influence market dynamics, given their heightened susceptibility to chronic diseases. With the global elderly population projected to nearly double by 2050, and the majority residing in low- and middle-income countries, there is an urgent need for effective CAD management solutions. This demographic trend, coupled with statistics from organizations like the British Heart Foundation, projecting a high burden of coronary heart disease, underscores the anticipated rise in demand for CAD management, thereby bolstering market growth.

  1. Introduction
    1. Research Objectives and Assumptions
    2. Research Methodology
    3. Abbreviations
  2. Market Definition & Study Scope
  3. Executive Summary
    1. Market Snapshot, By Drug Class
    2. Market Snapshot, By Distribution Channel

    3. Market Snapshot, By Region
  4. Global Coronary Artery Disease Therapeutics Market Dynamics
    1. Drivers, Restraints and Opportunities
      1. Drivers
        1. Rising Incidence of Coronary Artery Disease (CAD)
        2. Technological Advancements
        3. Growing Geriatric Population
      2. Restraints
        1. High Cost of Treatments
        2. Stringent Regulatory Requirements
        3. Lack of Awareness
      3. Opportunities
        1. Focus on Preventive Therapies
        2. Advancements in Gene Therapy
        3. Telemedicine and Remote Monitoring
    2. PEST Analysis
      1. Political Analysis
      2. Economic Analysis
      3. Social Analysis
      4. Technological Analysis
    3. Porter's Analysis
      1. Bargaining Power of Suppliers
      2. Bargaining Power of Buyers
      3. Threat of Substitutes
      4. Threat of New Entrants
      5. Competitive Rivalry

  5. Market Segmentation
    1. Global Coronary Artery Disease Therapeutics Market, By Drug Class, 2021 - 2031 (USD Million)
      1. Statins
      2. Beta-blockers
      3. Calcium Channel Blockers
      4. ACE Inhibitors
      5. Antiplatelet Drugs
      6. Others
    2. Global Coronary Artery Disease Therapeutics Market, By Distribution Channel , 2021 - 2031 (USD Million)
      1. Hospitals
      2. Online Pharmacies
      3. Retail Pharmacies
    3. Global Coronary Artery Disease Therapeutics Market, By Geography, 2021 - 2031 (USD Million)
      1. North America
        1. United States
        2. Canada
      2. Europe
        1. Germany
        2. United Kingdom
        3. France
        4. Italy
        5. Spain
        6. Nordic
        7. Benelux
        8. Rest of Europe
      3. Asia Pacific
        1. Japan
        2. China
        3. India
        4. Australia & New Zealand
        5. South Korea
        6. ASEAN (Association of South East Asian Countries)
        7. Rest of Asia Pacific
      4. Middle East & Africa
        1. GCC
        2. Israel
        3. South Africa
        4. Rest of Middle East & Africa
      5. Latin America
        1. Brazil
        2. Mexico
        3. Argentina
        4. Rest of Latin America
  6. Competitive Landscape
    1. Company Profiles
      1. AstraZeneca Plc
      2. Gilead Sciences, Inc
      3. Novartis AG
      4. Pfizer Inc
      5. Bayer AG
  7. Analyst Views
  8. Future Outlook of the Market